Vaccines to prevent HPV infection were orginally developed with the purpose of addressing disease of the genito-urinary tract. An additional benefit of vaccinating against HPV sub-types 6 and 11 is potential to drastically reduce the incidence of new case of recurrent respiratory papillomas.
Studies demonstrating the potential for preventing transmission of HPV in the aero-digestive tract will be presented along with the initial findings from the CDC-funded retrospective and prospective studies in the US and from Canada demonstrating early signs of reduction in incident and prevalent cases.
Preliminary results from the US and Canadian RRP registry studies will be presented along with correlated data regarding reduction in ano-genital warts.
Wide-spread HPV vaccination covering sub-types 6 and 11 has the potential to drastically reduce the incidence and future prevalence of RRP in populations that can acheive herd immunity.